The repeated covid-19 pneumonia epidemic and the complex and changeable international situation have brought challenges to the world economic recovery and the global industrial chain supply chain; Since March, China's new round of epidemic has also caused trouble and impact on the production and operation of enterprises, including foreign enterprises. Under multiple pressures, what are the intentions of foreign investors? Is confidence affected? The data of China's actual use of foreign capital in the first four months once again gave a positive answer, proving the charm of China's big market.
According to the data released by the Ministry of Commerce, from January to April 2022, the actual amount of foreign capital used in China was 478.61 billion yuan, a year-on-year increase of 20.5% (equivalent to US $74.47 billion, a year-on-year increase of 26.1%). In terms of industry, the actual amount of foreign capital used in the service industry was 351.94 billion yuan, a year-on-year increase of 12.5%. The actual use of foreign capital in high-tech industries increased by 45.6% year-on-year, including 36.7% in high-tech manufacturing and 48.3% in high-tech services. From the source, the actual investment in China of South Korea, the United States and Germany increased by 76.3%, 53.2% and 80.4% respectively. From the perspective of regional distribution, the actual use of foreign capital in eastern, central and Western China increased by 18.7%, 43.7% and 26.9% respectively year-on-year.
It is noteworthy that in the first four months, there were 185 new large projects with contractual foreign investment of more than US $100 million, which is equivalent to an average of 1.5 large foreign projects landing every day! What is more gratifying is that this trend continues.
On May 16, the cloud signing ceremony of foreign-funded projects in Jiangsu Province and the awarding ceremony of foreign-funded headquarters enterprises were held. At the ceremony, Suzhou Industrial Park was rated as the only provincial foreign-funded headquarters economic agglomeration area. At the same time, five major projects in Wuxi have achieved centralized signing. The total investment of these projects is US $740 million, involving medical devices, high-end equipment and high-end manufacturing, biomedicine and other fields.
Among them, sibman degenerative arthritis cell therapy project is a capital increase and expansion project of sibman Biotechnology (Wuxi) Co., Ltd. The company has invested 125 million US dollars since it settled in Wuxi, and plans to increase 75 million US dollars this year to build an industrialization base around related products. The person in charge of the enterprise disclosed that the phase II clinical trial of sibiman stem cell drug for the treatment of degenerative arthritis is about to be completed, and it can be conditionally listed after being approved by the State Food and drug administration. According to the regulations, the product production base of phase III clinical trial of products must be the official site for commercial production of products. This expansion stems from both confidence in the prospect of products and recognition of the development environment of Wuxi.
There are many foreign enterprises that continue to increase their investment. Recently, taipaisiqi group announced the official establishment of the group's China tourism retail headquarters in Hainan free trade port to further expand the layout of tourism retail business.
"With the continuous development and improvement of the construction of Hainan free trade port, the Hainan market continues to release strong potential energy. The vigorous development momentum and the continuously optimized business environment attract and encourage us to make great strides forward." Yang Baoyan, President of taipaisiqi Asia Pacific region and President and CEO of Kouchi China, told reporters that the official landing of taipaisiqi China tourism retail headquarters in Hainan marks a new chapter in the rapid development of the group's tourism retail business in China. In the future, the group hopes to join hands with more partners to deepen the market layout, stimulate the pre action energy with cooperation as the core, and fully meet the aspirations of Chinese consumers for a more personalized and better lifestyle.
Bayer Group, which has been rooted in China for 140 years, is also full of confidence in the Chinese market. "Over the past 140 years, Bayer has always taken root in China and served local patients, consumers and growers with its deep market accumulation and rich experience." Steve, chief financial officer of Bayer Greater China, said in an interview with reporters that Bayer has witnessed the process of China actively introducing policies and measures to inject vitality into the economy, help enterprises cope with operational challenges and promote the steady growth of the national economy. Facts have proved that China's efforts have been fruitful, which has also continued to strengthen the confidence of multinational companies in China, including Bayer.
In the face of the uncertainty brought by the recent epidemic, Bayer has always actively responded to relevant policies and measures, paid close attention to the daily health needs of the people, tried its best to cope with the challenges brought by uncertainty such as supply chain, and contributed to the stable supply of medical and health care and agricultural products.
It is reported that in the field of medicine and health, the production capacity improvement project of prescription drugs Beijing factory announced by Bayer in 2020 is expected to be put into use by the end of this year. The investment amount of the project exceeds 50 million euros. After completion, the annual production capacity of the Beijing plant is expected to increase by about 40%; The implementation of innovative digital solutions will also be accelerated, which will once again strengthen its important position as one of the most advanced production bases of Bayer prescription drugs in the world. In the field of agricultural science and technology, the new Chinese supply center of Bayer Crop Science in Hangzhou will lay the foundation this year and expand production capacity. Bayer has formulated a development strategy for the next 10 years. It will work with its Chinese partners to explore the path of digital agriculture, help Chinese farmers increase production and income, promote the sustainable and modern development of Chinese agriculture, and continue to make positive contributions to China's food security and Rural Revitalization.
"China is one of Bayer's most important strategic markets and plays an important role in global supply chain and innovation." Steve told reporters that in 2022, on the basis of having six production bases and two R & D centers, Bayer will continue to take root in China, increase local investment and cooperation, seize the opportunities brought by China's opening-up and write a more wonderful chapter of development with China.
